Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 1 | X017743 | — |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 2 | Y003449 | — |
no adverse event; first dose in August ,2024 and their second dose in October 2024 but have not received their third dose at this time; This spontaneous report was received from a physician and refers to a 19-year-old female patient. Her concurrent conditions, medical history and concomitant therapies were not provided. On an unknown date in August 2024, the patient was vaccinated with the first dose of hepatitis B vaccine (RECOMBIVAX HB) 0.5 ml, lot x017743, expiration date 21-FEB-2026 (route of administration and anatomical location were not provided) for prophylaxis. On an unknown date in October 2024, she was administered the second dose of hepatitis B vaccine (RECOMBIVAX HB) 0.5 ml, lot # y003449, expiration date 16-OCT-2026 (route of administration and anatomical location were not provided) for prophylaxis (Inappropriate schedule of product administration). At the time of the report, she did not receive the third dose of the suspect vaccine. No adverse events were reported.